Back to Search Start Over

The rescue and selection of thermally stable type O vaccine candidate strains of foot-and-mouth disease virus.

Authors :
Gao, Ya
Li, Pinghua
Ma, Xueqing
Bai, Xingwen
Sun, Pu
Du, Ping
Yuan, Hong
Cao, Yimei
Li, Kun
Fu, Yuanfang
Zhang, Jing
Bao, Huifang
Chen, Yingli
Li, Zhiyong
Lu, Zengjun
Liu, Zaixin
Li, Dong
Source :
Archives of Virology; Aug2021, Vol. 166 Issue 8, p2131-2140, 10p
Publication Year :
2021

Abstract

Inactivated foot-and-mouth disease virus (FMDV) vaccines have been used widely to control foot-and-mouth disease (FMD). However, the virions (146S) of this virus are easily dissociated into pentamer subunits (12S), which limits the immune protective efficacy of inactivated vaccines when the temperature is higher than 30 °C. A cold-chain system can maintain the quality of the vaccines, but such systems are usually not reliable in limited-resource settings. Thus, it is imperative to improve the thermostability of vaccine strains to guarantee the quality of the vaccines. In this study, four recombinant FMDV strains containing single or multiple amino acid substitutions in the structural proteins were rescued using a previously constructed FMDV type O full-length infectious clone (pO/DY-VP1). We found that single or multiple amino acid substitutions in the structural proteins affected viral replication to different degrees. Furthermore, the heat and acid stability of the recombinant viruses was significantly increased when compared with the parental virus. Three thermally stable recombinant viruses (rHN/DY-VP1<superscript>Y2098F</superscript>, rHN/DY-VP1<superscript>V2090A-S2093H</superscript>, and rHN/DY-VP1<superscript>V2090A-S2093H-Y2098F</superscript>) were prepared as inactivated vaccines to immunize pigs. Blood samples were collected every week to prepare sera, and a virus neutralization test showed that the substitutions S2093H and Y2098F, separately or in combination, did not affect the immunogenicity of the virus, but the Y2098F mutation increased the thermostability significantly (p < 0.05). Therefore, the rHN/DY-VP1<superscript>Y2098F</superscript> mutant should be considered for use in future vaccines. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03048608
Volume :
166
Issue :
8
Database :
Complementary Index
Journal :
Archives of Virology
Publication Type :
Academic Journal
Accession number :
151332756
Full Text :
https://doi.org/10.1007/s00705-021-05100-3